Ocular Therapeutix (OCUL) Announces Board and Leadership Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
February 22, 2024 7:30 AM ESTIndustry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair
Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become Chief Strategy Officer
Addition of Strategic and Clinical Experts Puts Ocular on Track to be a Leader in Retina Care
Expanded Team Anticipated to Accelerate Momentum in AXPAXLI Phase 3 Wet AMD Programs
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, Ocular), a... More
